Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5745417 | 1.00 | LMNA (0.43) | LMNAMAPK1SRCCYP2D6CES2 | |
| SCHEMBL5745420 | 0.84 | LMNA (0.41) | LMNAMAPK1SRCCYP2D6CES2 | |
| SCHEMBL64260 | 0.84 | LMNA (0.41) | LMNAMAPK1SRCCYP2D6CES2 | |
| SCHEMBL9634198 | 0.81 | LMNA (0.39) | LMNAMAPK1SRCCYP2D6CES2 | |
| SCHEMBL3199543 | 0.80 | TSHR (0.42) | LMNAMAPK1CYP2D6TSHRALDH1A1 | |
| SCHEMBL2637053 | 0.78 | MAPT (0.33) | KMT2ATSHRALDH1A1POLB | |
| SCHEMBL8173540 | 0.77 | CYP2D6 (0.34) | LMNAMAPK1SRCCYP2D6CES2 | |
| Butane SCHEMBL23346235 | 0.77 | POLB (0.45) | LMNAMAPK1KMT2ATSHRPOLB | |
| SCHEMBL5573454 | 0.77 | UGT2B7 (0.52) | CYP2D6KMT2ATSHR | |
| SCHEMBL767297 | 0.76 | IDO1 (0.39) | LMNAMAPK1SRCCYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4087931-B1 | NOVEL TLR9 AGONISTS | SBI BIOTECH CO LTD (JP) | 2024-12-25 | — | — | EP | disclosed |
| WO-2024127215-A2 | IMMUNOGENIC COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE AGAINST CLOSTRIDIOIDES (CLOSTRIDIUM) DIFFICILE | PFIZER INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240189410-A1 | IMMUNOGENIC COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE AGAINST CLOSTRIDIOIDES (CLOSTRIDIUM) DIFFICILE | PFIZER (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240100132-A1 | MODULATION OF AAV-BASED GENE EXPRESSION | PREVAIL THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | US | disclosed |
| US-11827886-B2 | Compositions and methods for modulating dysferlin expression | UNIVERSITY OF MASSACHUSETTS (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230323368-A1 | NOVEL TLR9 AGONISTS | SBI BIOTECH CO., LTD. (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20230203504-A1 | IMMUNOMODULATORY POLYNUCLEOTIDES AND USES THEREOF | CHANGCHUN HUAPU BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| EP-4087931-A1 | NOVEL TLR9 AGONISTS | SBI Biotech Co., Ltd. (JP) | 2022-11-16 | — | — | EP | disclosed |
| US-11326170-B2 | Immunomodulatory polynucleotides and uses thereof | CHANGCHUN HUAPU BIOTECHNOLOGY CO. LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| US-11110158-B2 | Prostate-associated antigens and vaccine-based immunotherapy regimens | PFIZER INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-6472521-B1 | Oligonucleotides for the inhibition of human eg5 expression | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-29 | — | — | US | disclosed |
| US-20010021772-A1 | SHORT OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-09-13 | — | — | US | disclosed |
| EP-1102842-A2 | ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | Aventis Pharma Deutschland GmbH (DE) | 2001-05-30 | — | — | EP | disclosed |
| EP-1100894-A2 | SHORT OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | Aventis Pharma Deutschland GmbH (DE) | 2001-05-23 | — | — | EP | disclosed |
| US-6090969-A | REACTING AN OPTICALLY ACTIVE BINAPHTHOL WITH AN ALKALI METAL ALUMINUM HYDRIDE OR A DIALKYLALUMINUM HYDRIDE AND AN ALKALI OR ALKALINE EARTH METAL BASE | NAGASE AND CO., LTD. (JP) | 2000-07-18 | — | — | US | disclosed |
| WO-2000008140-A2 | ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-02-17 | — | — | WO | disclosed |
| WO-2000008141-A2 | SHORT OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-02-17 | — | — | WO | disclosed |
| EP-0979869-A1 | Short oligonucleotides for the inhibition of VEGF expression | Hoechst Marion Roussel Deutschland GmbH (DE) | 2000-02-16 | — | — | EP | disclosed |
| EP-0978561-A1 | Antisense oligonucleotides for the inhibition of VEGF expression | Hoechst Marion Roussel Deutschland GmbH (DE) | 2000-02-09 | — | — | EP | disclosed |
| US-5847186-A | Process for preparing asymmetric compound by using metal complex | NAGASE & COMPANY, LTD. (JP) | 1998-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203504-A1 | IMMUNOMODULATORY POLYNUCLEOTIDES AND USES THEREOF | TLR3, TLR9, CD47 | LMNA 3086/4885MAPK1 3742/4885SRC 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.